Maria Karasarides leads medical strategy and innovation for the oncology early development portfolio. With an applied focus on innovative technologies and biomarkers, she oversees the integration of medical research designed to address real-world problems that impede clinical outcomes and meaningfully bridge research into clinical practice and patient care. Her experience spans the academic and pharmaceutical sectors with a focus on clinical and translational development. She held leadership positions at Regeneron Pharmaceuticals, AstraZeneca and Bristol Myers Squibb where she advanced the development of investigational immune modulating therapies, durvalumab (ImfinziTM) & tremelimumab based combinations, and was a key member of the ipilimumab (Yervoy®) launch team. Dr. Karasarides holds a Ph.D. in biology/biochemistry and conducted her graduate work on RAS/PI3K signaling at the Lerner Research Institute, Cleveland Clinical Foundation. During her post-doctoral fellowship at the Institute of Cancer Research, London, UK, she delineated BRAF as a therapeutic target in melanoma.
William Oh, Mount Sinai